Perceptive Advisors LLC Zentalis Pharmaceuticals, Inc. Transaction History

Perceptive Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$17.91 - $52.25 $8.98 Million - $26.2 Million	-501,509 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$41.58 - $80.89 $2.95 Million - $5.74 Million	70,965 Added 16.48%	501,509 $23.1 Million
Q4 2021 Feb 14, 2022	BUY	$66.92 - $84.79 $28.8 Million - $36.5 Million	430,544 New	430,544 $36.2 Million
Q1 2021 May 17, 2021	SELL	$35.69 - $52.72 $37.5 Million - $55.4 Million	-1,050,003 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$23.2 - $54.8 $24.4 Million - $57.5 Million	1,050,003 New	1,050,003 $45.8 Million

142

68M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $198M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.